The Recall Desk

Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Filters

Agency

Category

Minimum severity

Clear filters

9251–9275 of 11860

  • SevereFDA (Drugs)·D-862-2015·2015-04-29

    Primaquine Phosphate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Primaquine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Primaquine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-526-2015·2015-04-29

    Atazanavir API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Atazanavir active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Atazanavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-798-2015·2015-04-29

    Miltefosine API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Miltefosine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Miltefosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-647-2015·2015-04-29

    Attix Pharmaceuticals Recalls EDTA Dipotassium Magnesium Salt Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-825-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ondansetron HCl Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ondansetron HCl Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ondansetron HCl Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-661-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ethinyl Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Ethinyl Estradiol active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Ethinyl Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-709-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Ophthalmic Grade) because it was repackaged in a facility with penicillin products, posing a cross-contamination risk.

    Product
    Hyaluronic Acid Sodium Salt (Ophthalmic Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-557-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcium Sulfate Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Calcium Sulfate Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Calcium Sulfate Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-800-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minoxidil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minoxidil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minoxidil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-654-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Non-Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Non-Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-552-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupivacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bupivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-640-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxorubicin HCI Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Doxorubicin HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Doxorubicin HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-566-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefadroxil Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefadroxil Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cefadroxil Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-781-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metformin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metformin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metformin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-774-2015·2015-04-29

    Attix Pharmaceuticals Recalls Meclofenoxate HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Meclofenoxate HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Meclofenoxate HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-540-2015·2015-04-29

    Attix Pharmaceuticals Recalls Betahistine Dihydrochloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Betahistine Dihydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Betahistine Dihydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-529-2015·2015-04-29

    Atropine Sulfate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Atropine Sulfate Monohydrate USP active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Atropine Sulfate Monohydrate USP active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-565-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carvedilol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carvedilol active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Carvedilol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-532-2015·2015-04-29

    Attix Pharmaceuticals Recalls Azelastine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Azelastine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Azelastine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-638-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dopamine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dopamine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dopamine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-533-2015·2015-04-29

    Attix Pharmaceuticals Recalls Azithromycin Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Azithromycin Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Azithromycin Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-498-2015·2015-04-29

    Attix Pharmaceuticals Recalls 2-Methoxyestradiol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2-Methoxyestradiol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2-Methoxyestradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-698-2015·2015-04-29

    Gefitinib API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Gefitinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Gefitinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-922-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tetracaine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tetracaine (free base) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tetracaine (free base) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-731-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imiquimod Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Imiquimod active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imiquimod active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide